Review
Medicine, Research & Experimental
Jianing Gong, Taoran Shi, Jinfeng Liu, Zerong Pei, Jingbo Liu, Xiaoliang Ren, Fengyun Li, Feng Qiu
Summary: Multidrug resistance (MDR) promotes tumor recurrence and metastasis and reduces anticancer efficiency. Conventional chemotherapy fails to achieve optimal therapeutic effect and accelerates MDR. Dual-drug codelivery nanosystems combine dual-drug administration with nanotechnology to overcome the limitations of free drugs. The characteristics of nanoparticles and the synergistic effect of dual drugs help circumvent various drug-resistant mechanisms.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Pharmacology & Pharmacy
Suhaila O. Alhaj-Suliman, Emad I. Wafa, Aliasger K. Salem
Summary: In the past two decades, there has been increasing interdisciplinary research on the development of nanoparticles for medical applications. However, nanoparticles still face biological barriers and biodistribution challenges, limiting their overall clinical potential. To overcome these limitations, innovative modifications have been made to nanoparticle formulations designed for cancer imaging and treatment, aiming to enhance specificity and target diseased tissues. Recent advancements in technology and chemistry have been employed to modify the surface and characteristics of nanoparticles, in combination with identifying critical biomarkers, providing new strategies for improving nanoparticle specificity in cancer diagnosis and therapy. This review discusses the latest advances in nanoparticle design and engineering, and outlines future directions for the development of next-generation nanomedicines.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Review
Pharmacology & Pharmacy
Mahmoud Zaki El-Readi, Ahmed M. Al-Abd, Mohammad A. Althubiti, Riyad A. Almaimani, Hiba Saeed Al-Amoodi, Mohamed Lotfy Ashour, Michael Wink, Safaa Yehia Eid
Summary: Plant secondary metabolites are commonly used in pharmaceutical agents, especially in cancer therapy, to reduce the doses of chemotherapeutic drugs, enhance cell growth inhibition, avoid side effects, and increase cancer cell sensitivity to chemotherapy. They interact with membrane proteins and nucleic acids, inducing apoptosis to overcome multidrug resistance. Consuming dietary supplements containing secondary metabolites may affect the bioavailability, efficacy, and safety of drugs that are substrates of P-glycoprotein.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Chung-Pu Wu, Sung-Han Hsiao, Yu-Shan Wu
Summary: The overexpression of human ATP-binding cassette (ABC) transporters in cancer cells can lead to multidrug resistance (MDR), which poses a significant obstacle to chemotherapy. Currently, there are no approved drugs specifically designed to treat multidrug-resistant cancers. However, drug repurposing has emerged as a practical approach to discover effective modulators of drug transporters.
DRUG RESISTANCE UPDATES
(2023)
Article
Cell Biology
Myeong Jin Kim, Hyung Sun Kim, Hyeon Woong Kang, Da Eun Lee, Woosol Chris Hong, Ju Hyun Kim, Minsoo Kim, Jae-Ho Cheong, Hyo Jung Kim, Joon Seong Park
Summary: Pancreatic cancer patients often have poor outcomes with gemcitabine treatment due to chemoresistance. This study identified SLC38A5 as a potential therapeutic target for gemcitabine-resistant pancreatic cancer. Inhibition of SLC38A5 decreased cell proliferation and migration, triggered ferroptosis signaling pathway, and restored gemcitabine sensitivity in animal models. These findings suggest SLC38A5 could be a novel target for overcoming gemcitabine resistance in pancreatic cancer therapy.
Article
Chemistry, Medicinal
Chang Hyun Kim, Sangkil Lee, Ji Yeh Choi, Min Jeong Lyu, Hyun Min Jung, Yoon Tae Goo, Myung Joo Kang, Young Wook Choi
Summary: This study compared the simultaneous drug delivery efficiency of a co-loaded single-carrier system named D boolean AND T-PRN with a physically mixed dual-carrier system of D-PRN and T-PRN to overcome drug resistance in breast cancer cells. The results showed that D boolean AND T-PRN exhibited the highest MDR reversal efficiency and improved cytotoxicity and apoptosis in MCF7/ADR cells. In addition, the single nanocarrier system demonstrated better intracellular delivery efficiency. In MCF7/ADR-xenografted mouse models, simultaneous DTX and TRQ delivery using D boolean AND T-PRN significantly suppressed tumor growth. These findings suggest that the co-loaded system DTX/TRQ (1:1, w/w) is a promising therapeutic strategy for drug-resistant breast cancer cells.
Review
Materials Science, Biomaterials
Bruna G. Carvalho, Franciele F. Vit, Hernandes F. Carvalho, Sang W. Han, Lucimara G. de la Torre
Summary: Nanocarrier delivery systems have been developed to overcome the multidrug-resistance of cells to antineoplastic medicines, allowing for more effective treatment. Co-delivery of different agents such as drugs and genetic materials can achieve synergistic therapeutic effects. Future trends involve designing novel nano-scale platforms for co-delivering therapeutic agents.
JOURNAL OF MATERIALS CHEMISTRY B
(2021)
Article
Chemistry, Multidisciplinary
Yanran Li, Zigui Wang, Yanxin Qi, Zhaohui Tang, Xiaoyuan Li, Yubin Huang
Summary: In this study, a Pt-IV prodrug that can be activated in a spatiotemporally controllable manner inside the mitochondria of cancer cells was designed. The prodrug effectively released cisplatin upon red light exposure, leading to increased cytotoxicity and accumulation in cancer cells. This work demonstrates the potential of controllably activated and mitochondrion-targeting Pt-IV prodrugs to overcome chemotherapy drug resistance.
CHEMICAL COMMUNICATIONS
(2022)
Article
Biotechnology & Applied Microbiology
Wenrui Wang, Mengyang Zhou, Yang Xu, Wei Peng, Shiwen Zhang, Rongjie Li, Han Zhang, Hui Zhang, Shumin Cheng, Youjing Wang, Xinyu Wei, Chengxu Yue, Qingling Yang, Changjie Chen
Summary: The study successfully formulated TPGS-Res-SLNs nanoparticles to improve therapeutic efficacy against breast cancer, showing significant anti-tumor activity and promotion of cell apoptosis. It also exhibited significant inhibition of cancer cell invasion and migration. In vivo experiments showed that TPGS-Res-SLNs had higher efficacy in promoting tumor cell apoptosis.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Kaipei Luo, Feng Xu, Tianyi Yao, Jianping Zhu, Hua Yu, Guangji Wang, Juan Li
Summary: A dual-modified lipid albumin nanosystem was developed for targeted delivery of paclitaxel to treat multidrug-resistant cancer. The system showed improved intracellular accumulation of the drug and demonstrated excellent antitumor efficacy by inhibiting cell proliferation through controlled drug release within cells. In vivo studies confirmed elevated tumor accumulation and significant survival benefits in tumor-bearing mice, showcasing the potential of this system for targeted chemotherapy and overcoming multidrug resistance in cancer treatment.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2021)
Article
Nanoscience & Nanotechnology
Changjoon Keum, Jiyoung Hong, Doyeon Kim, Sang-Yup Lee, Hyuncheol Kim
Summary: Research presents lysosome-targeted self-assembly of PDI derivatives as an effective and selective anticancer therapy, causing cancer cell apoptosis through lysosomal rupture; compared to chemotherapeutic agents, PDI-AAs display higher anticancer efficacy on MDR cancer cells.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Pharmacology & Pharmacy
Chih-Peng Lin, Shu-Hui Wu, Tzu-Yin Lin, Chia-Hui Chu, Leu-Wei Lo, Ching-Chuan Kuo, Jang-Yang Chang, Szu-Chun Hsu, Bor-Sheng Ko, Ming Yao, Jong-Kai Hsiao, Shih-Wei Wang, Dong-Ming Huang
Summary: This study develops a simple and versatile biological drug delivery system (bDDS) based on human red blood cell-derived vesicles (RDVs), which shows excellent biocompatibility for cancer chemotherapy. The bDDS, named Dox-gluRDVs, effectively suppress multidrug resistance in uterine sarcoma by inducing cell death through a lysosomal-mitochondrial axis-dependent mechanism.
PHARMACOLOGICAL RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Tuyelee Das, Uttpal Anand, Swaroop Kumar Pandey, Charles R. Ashby, Yehuda G. Assaraf, Zhe-Sheng Chen, Abhijit Dey
Summary: This article discusses the main cause of cancer chemotherapy resistance, which is multidrug resistance. The mechanisms of resistance to paclitaxel and docetaxel are explored, including alterations in microtubule-protein interactions and the expression of multidrug efflux transporters. Additionally, various pharmacological modulations and herbal formulations for reversing paclitaxel resistance are discussed, indicating a new era in modern medicine to combat multidrug resistance in cancer patients.
DRUG RESISTANCE UPDATES
(2021)
Review
Pharmacology & Pharmacy
Martin Majernik, Rastislav Jendzelovsky, Jana Vargova, Zuzana Jendzelovska, Peter Fedorocko
Summary: Photodynamic therapy (PDT) for cancer has advantages over conventional therapeutic approaches, but multidrug resistance is a major limitation. The use of dynamic nanoplatforms can minimize the effect of multidrug resistance and significantly enhance the therapeutic efficacy of PDT. Additionally, nanoparticles can induce synergistic effects when used in combination treatments and improve the target potential in multidrug resistant and cancer stem cells.
Article
Pharmacology & Pharmacy
Xu Wu, Chun Yin, Jiang Ma, Stella Chai, Chunyuan Zhang, Sheng Yao, Onat Kadioglu, Thomas Efferth, Yang Ye, Kenneth Kin-Wah To, Ge Lin
Summary: The study found that three polyoxypregnanes from Marsdenia tenacissima were transformed by intestinal microbiota into active metabolites that could inhibit ABCB1 efflux activity, restore cancer cell sensitivity to chemotherapy, and had the potential to be safe, effective, and specific pro-drugs for reversing ABCB1-mediated multidrug resistance.
ACTA PHARMACEUTICA SINICA B
(2021)
Review
Biotechnology & Applied Microbiology
Neha N. Parayath, Srujan K. Gandham, Mansoor M. Amiji
Summary: miRNAs are important messenger molecules in the tumor microenvironment, playing key roles in immune suppression, tumor progression, metastasis, and resistance. This review discusses nanomedicine strategies for achieving cell-specific delivery of miRNAs. The main goal of delivery is to activate the tumor immune landscape and prevent chemotherapy resistance. Specifically, the use of hyaluronic acid-based nanoparticle miRNA delivery to the tumor microenvironment is discussed.
Article
Biochemistry & Molecular Biology
Kevin Craig, Marc Abrams, Mansoor Amiji
Summary: Despite current clinical programs focusing on reducing hepatic fat accumulation to prevent inflammation and fibrosis in nonalcoholic fatty liver disease (NAFLD), research suggests that liver inflammation may play a critical role in the development of the disease. A simple cholesterol-siRNA conjugate system has shown potential in targeting liver inflammation and preventing the hallmarks of NAFLD in preclinical models, providing evidence for a novel therapeutic approach using RNA interference.
NUCLEIC ACID THERAPEUTICS
(2023)
Article
Cell Biology
Lucia Casadei, Patricia Sarchet, Fernanda Costas C. de Faria, Federica Calore, Giovanni Nigita, Sayumi Tahara, Luciano Cascione, Martin Wabitsch, Francis J. Hornicek, Valerie Grignol, Carlo M. Croce, Raphael E. Pollock
Summary: EVs have emerged as an important player in tumor initiation, progression, and metastasis. Detection of EV cargoes remains a challenge, and this study demonstrates the potential of using ultrasensitive ISH to examine embedded EVs as substrates for detecting DNA amplification, providing a more direct visualization of DNA targets.
JOURNAL OF EXTRACELLULAR VESICLES
(2022)
Article
Allergy
Di Huang, Maie S. Taha, Angela L. Nocera, Alan D. Workman, Mansoor M. Amiji, Benjamin S. Bleier
Summary: Nasal epithelium-derived extracellular vesicles (EVs) play a crucial role in antiviral immunity by delivering functional miR-17 and directly neutralizing viral infections. However, cold exposure can impair EV secretion, microRNA packaging, and antiviral binding, leading to weakened antiviral effects.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Smrithi Padmakumar, Anisha D'Souza, Neha N. Parayath, Benjamin S. Bleier, Mansoor M. Amiji
Summary: Nucleic acid therapeutics, delivered through non-viral vectors, have shown advanced efficacy in treating central nervous system diseases. However, challenges such as the blood-brain barrier, complex pathophysiological changes, and the presence of non-dividing cells need to be overcome for successful therapy. Extensive scientific efforts are being made to optimize non-invasive and safer administration approaches for clinical translation.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Orthopedics
David S. Constantinescu, William Pavlis, Juan J. Lizardi, Jonathan Weinerman, Thomas M. Best, Francis J. Hornicek, Seth D. Dodds
Summary: The purpose of this review was to analyze the types of questions in the Orthopaedic In-Training Examination. The study found that musculoskeletal trauma had the highest number of questions, and residents should focus on clinical management topics and primary journal sources for studying.
JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
(2023)
Article
Medicine, Research & Experimental
Maie S. Taha, Shallu Kutlehria, Anisha D'Souza, Benjamin S. Bleier, Mansoor M. Amiji
Summary: Verapamil, a calcium channel blocker, shows potential for treating chronic rhinosinusitis (CRS) with or without nasal polyps. However, its dose is limited by side effects, making localized intranasal administration preferable. The challenge with intranasal administration is mucociliary clearance, which reduces localized drug availability. To overcome this challenge, verapamil was loaded into mucoadhesive cationic polyethylene glycol-modified (PEGylated) liposomes. This formulation increased tissue residence time and nasal tissue accumulation of verapamil, making it a promising intranasal delivery system for CRS therapy.
MOLECULAR PHARMACEUTICS
(2023)
Review
Chemistry, Multidisciplinary
Anisha D'Souza, Saeideh Nozohouri, Benjamin S. Bleier, Mansoor M. Amiji
Summary: Nucleic acid-based therapeutic molecules have great potential for treating diseases in the CNS, but delivering them to the brain's target cells and sub-cellular compartments is a challenge. This review discusses the challenges and recent advances in cellular and sub-cellular delivery using various mechanisms and routes of administration.
PHARMACEUTICAL RESEARCH
(2023)
Article
Oncology
Ishita Chen, Abraham J. Wu, Andrew Jackson, Purvi Patel, Lian Sun, Angela Ng, Aditi Iyer, Aditya Apte, Andreas Rimner, Daniel Gomez, Joseph O. Deasy, Maria Thor
Summary: Pulmonary toxicity is a limiting factor in SBRT for tumors near PBT, esophagus, or other mediastinal structures. Published models of pulmonary toxicity were explored in an independent cohort of patients. Seven NTCP models were identified and the Dmax model best described pulmonary toxicity in this cohort.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Article
Pathology
Stefan C. Halvorsen, Yair Benita, Megan Hopton, Brooke Hoppe, Hilmar O. Gunnlaugsson, Parimal Korgaonkar, Charles R. Vanderburg, G. Petur Nielsen, Nicole Trepanowski, Jaime H. Cheah, Matthew P. Frosch, Joseph H. Schwab, Andrew E. Rosenberg, Francis J. Hornicek, Slim Sassi
Summary: This study compared the gene expression profiles of chordoma and notochord, and found consistency between the two, identifying a 12-gene diagnostic signature for chordoma. The TBXT/TGF-B/SOX6/SOX9 pathway was hyperactivated in the tumor, suggesting that chondrogenesis-related pathways play a key role in chordoma development. This research provided the first molecular connection between notochord and chordoma and identified potential therapeutic targets.
AMERICAN JOURNAL OF PATHOLOGY
(2023)
Review
Pharmacology & Pharmacy
Hiba Hussain, Aishwarya Ganesh, Lara Milane, Mansoor Amiji
Summary: This article mainly discusses the biology of SARS-CoV-2, vaccine formulations and trials, the concept of 'herd resistance,' and the vaccination divide. The COVID-19 pandemic has changed the landscape of medicine, with the rapid approval of vaccines leading to more accelerated trials. However, the low efficacy of current vaccines and the rapid mutation rate of the virus are preventing herd immunity and leading to the acquisition of herd resistance. Even with future, more effective vaccines, anti-vaccination attitudes will continue to challenge the quest for SARS-CoV-2 herd immunity.
EXPERT OPINION ON DRUG DELIVERY
(2023)
Review
Cell Biology
Michael G. G. Rizzo, Thomas M. M. Best, Johnny Huard, Marc Philippon, Francis Hornicek, Zhenfeng Duan, Anthony J. J. Griswold, Lee D. D. Kaplan, Joshua M. M. Hare, Dimitrios Kouroupis
Summary: Osteoarthritis (OA) is the leading cause of disability among the elderly and is increasingly affecting younger individuals. Recent advancements in understanding the pathology of OA have led to the identification of potential therapeutic approaches targeting specific molecular pathways, such as inflammation and cellular senescence. Stem cell therapies and senolytics show promise in controlling patient symptoms and slowing disease progression.
Article
Engineering, Biomedical
Kanika Suri, Anisha D'Souza, Di Huang, Aashray Bhavsar, Mansoor Amiji
Summary: Cancer therapy is shifting towards immunotherapy that activates the host immune system. Bacterial extracellular vesicles (BEVs) are being studied as a potential tool for controlling immune responses and for drug delivery. However, there are still unanswered questions regarding the use of BEVs, especially for long-term immunotherapies.
BIOACTIVE MATERIALS
(2023)
Review
Pharmacology & Pharmacy
Ketki Bhise, Navnath S. Gavande, Arun K. Iyer
Summary: Current treatment strategies for TNBC include conventional chemotherapy, immunotherapy, or a combination of both. Different drugs are used depending on the stage of the disease, with anthracyclines, alkylating agents, antimicrotubule agents, and antimetabolites being commonly used for early-stage TNBC, and antimetabolites, non-taxane microtubule inhibitors, and cross-linker platinums for late-stage TNBC. Newer options such as PARP inhibitors and immune checkpoint inhibitors have emerged for advanced TNBC cases where surgery is not an option. This review focuses on hypoxia-inspired treatment strategies for TNBC and provides an overview of ongoing clinical trials.
DRUG DISCOVERY TODAY
(2023)
Review
Biotechnology & Applied Microbiology
Andy J. Chua, Valentina Di Francesco, Di Huang, Anisha D'Souza, Benjamin S. Bleier, Mansoor M. Amiji
Summary: Chronic rhinosinusitis (CRS) is a prevalent and burdensome inflammatory disease that affects patients' quality of life. Nanotechnology provides potential solutions to enhance the effectiveness of topical therapies and overcome the limitations of current treatments. This review discusses the successful application of nanomedicine in CRS therapeutics, current limitations, and future opportunities.
